183 related articles for article (PubMed ID: 33342000)
1. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance.
Lindsay J; Othman J; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Pergam SA; Liu C; Slavin MA; Greenwood M
Transpl Infect Dis; 2021 Jun; 23(3):e13548. PubMed ID: 33342000
[TBL] [Abstract][Full Text] [Related]
2. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
3. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
[TBL] [Abstract][Full Text] [Related]
4. Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection.
Douglas G; Yong MK; Tio SY; Chau M; Prabahran A; Sasadeusz J; Slavin M; Ritchie D; Chee L
Transpl Infect Dis; 2023 Feb; 25(1):e13994. PubMed ID: 36413495
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
Chemaly RF; El Haddad L; Winston DJ; Rowley SD; Mulane KM; Chandrasekar P; Avery RK; Hari P; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; Dadwal SS; Blanchard T; Shah DP; Jiang Y; Ariza-Heredia E
Clin Infect Dis; 2020 Dec; 71(9):2365-2374. PubMed ID: 32076709
[TBL] [Abstract][Full Text] [Related]
7. Analysis of spontaneous cytomegalovirus clearance after low level reactivation using a pre-emptive treatment threshold of 4,000 IU/mL in allogeneic hematopoietic cell transplant recipients.
Walling M; Seago K; Dillaman M; Yingling S; Wen S; Veltri L; Ross KG; Cumpston A
J Infect Chemother; 2024 May; ():. PubMed ID: 38815653
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
Tan SK; Waggoner JJ; Pinsky BA
J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
[TBL] [Abstract][Full Text] [Related]
9. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
[TBL] [Abstract][Full Text] [Related]
10. Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation.
Kaur R; Purtill D; Cooney J; Cannell P; Wright M; Copeland TS; McGuire M; Boan P
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14147. PubMed ID: 37676725
[TBL] [Abstract][Full Text] [Related]
11. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
[TBL] [Abstract][Full Text] [Related]
12. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
13. Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status.
Damlaj M; Khalid F; Alahmari B; Alaskar A; Ghazi S; Johani S; AlSaedy A; Bosaeed M; Alhejazi A; Al-Zahrani M
Curr Res Transl Med; 2020 Aug; 68(3):131-137. PubMed ID: 32620466
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation.
Karantoni E; Zavras PD; Su Y; Fang J; Tamari R; Cho C; Perales MA; Stern A; Papanicolaou GA
Transplant Cell Ther; 2022 Jul; 28(7):403.e1-403.e7. PubMed ID: 35476955
[TBL] [Abstract][Full Text] [Related]
15. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters.
Chan ST; Logan AC
Blood Rev; 2017 May; 31(3):173-183. PubMed ID: 28173959
[TBL] [Abstract][Full Text] [Related]
16. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
18. Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring.
Yong MK; Ananda-Rajah M; Cameron PU; Morrissey CO; Spencer A; Ritchie D; Cheng AC; Lewin SR; Slavin M
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1961-1967. PubMed ID: 28797778
[TBL] [Abstract][Full Text] [Related]
19. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
[TBL] [Abstract][Full Text] [Related]
20. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]